# Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans

> **NCT07478133** · NA · COMPLETED · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 72 (actual)

## Conditions studied

- Pruritus

## Interventions

- **DRUG:** Nalfurafine Hydrochloride Orally Disintegrating Tablets
- **DRUG:** Remitch®

## Key facts

- **NCT ID:** NCT07478133
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-24
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-14
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478133, "Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT07478133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*